Literature DB >> 30756523

Correlation of creatinine- and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users.

Marilyn A Huestis1,2, Benjamin C Blount3, Daniel F Milan3, Matthew N Newmeyer1,4, Jennifer Schroeder5, Michael L Smith6.   

Abstract

Variability in urine dilution complicates urine cannabinoid test interpretation. Normalizing urine cannabinoid concentrations to specific gravity (SG) or creatinine was proposed to account for donors' hydration states. In this study, all urine voids were individually collected from eight frequent and eight occasional cannabis users for up to 85 hours after each received on separate occasions 50.6 mg Δ9-tetrahydrocannabinol (THC) by smoking, vaporization, and oral ingestion in a randomized, within-subject, double-blind, double-dummy, placebo-controlled protocol. Each urine void was analyzed for 11 cannabinoids and phase I and II metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS), SG, and creatinine. Normalized urine concentrations were log10 transformed to create normal distributions, and Pearson correlation coefficients determined the degree of association between the two normalization methods. Repeated-measures linear regression determined if the degree of association differed by frequent or occasional cannabis use, or route of administration after adjusting for gender and time since dosing. Of 1880 urine samples examined, only 11-nor-9-carboxy-THC (THCCOOH), THCCOOH-glucuronide, THC-glucuronide, and 11-nor-9-carboxy-Δ9-tetrahydrocannabivarin (THCVCOOH) were greater than the method's limits of quantification (LOQs). Associations between SG- and creatinine-normalized concentrations exceeded 0.90. Repeated-measures regression analysis found small but statistically significant differences in the degree of association between normalization methods for THCCOOH and THCCOOH-glucuronide in frequent vs occasional smokers, and in THCVCOOH and THC-glucuronide by route of administration. For the first time, SG- and creatinine-normalized urine cannabinoid concentrations were evaluated in frequent and occasional cannabis users and following oral, smoked, and inhaled cannabis. Both normalization methods reduced variability, improving the interpretation of urine cannabinoid concentrations and methods were strongly correlated. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  creatinine; specific gravity; urine cannabinoids

Year:  2019        PMID: 30756523     DOI: 10.1002/dta.2576

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  4 in total

1.  Erratum To: Implementation of a Blind Quality Control Program in Blood Alcohol Analysis.

Authors:  Jackeline Moral; Callan Hundl; Dayong Lee; Maddisen Neuman; Aimee Grimaldi; Maria Cuellar; Peter Stout
Journal:  J Anal Toxicol       Date:  2021-05-14       Impact factor: 3.367

2.  Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users.

Authors:  Marilyn A Huestis; Cristina Sempio; Matthew N Newmeyer; Maria Andersson; Allan J Barnes; Osama A Abulseoud; Benjamin C Blount; Jennifer Schroeder; Michael L Smith
Journal:  J Anal Toxicol       Date:  2020-10-12       Impact factor: 3.367

3.  Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users.

Authors:  Tory R Spindle; Edward J Cone; Nicolas J Schlienz; John M Mitchell; George E Bigelow; Ronald Flegel; Eugene Hayes; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2020-01-07       Impact factor: 3.367

4.  Preliminary Evidence for Cannabis and Nicotine Urinary Metabolites as Predictors of Verbal Memory Performance and Learning Among Young Adults.

Authors:  Natasha E Wade; Rachel Baca; Kelly E Courtney; Connor J McCabe; M Alejandra Infante; Marilyn A Huestis; Joanna Jacobus
Journal:  J Int Neuropsychol Soc       Date:  2021-07       Impact factor: 2.892

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.